Adenoviral Vectors for Gene Therapy, Second Edition provides detailed, comprehensive coverage of the gene delivery vehicles that are based on the adenovirus that is emerging as an important tool in gene therapy. These exciting new therapeutic agents have great potential for the treatment of disease, making gene therapy a fast-growing field for research. This book presents topics ranging from the basic biology of adenoviruses, through the construction and purification of adenoviral vectors, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models, with final consideration of the regulatory issues surrounding human clinical gene therapy trials. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors.
Advanced Biologic Drugs and Manufacturing Process explains in detail biologic drugs and their pharmaceutical charters and their significance in curing life-threatening chronic diseases. It also provides the latest information on the use of biological drugs for the treatment of numerous diseases and conditions and their most advanced therapies available, including how biologics have impacted cancer therapy, delayed or reversed the course of immune-related conditions, and changed the lives of those with rare chronic diseases. In addition, the book explains how immunotherapy is used for the treatment of diseases by activating or suppressing the immune system and how to find a way to more treatment options and access life-saving biologic drugs at a reasonable budget or to develop a generic version of a reference a biologic drug.Scientists working on the front lines in the biotechnology industry are provided with an overview on stable production processes and how to monitor the value chain transfer process of biologic drug for better return, in terms of profit. The book also helps researchers and academics on how to develop and update protocols related to testing, quality control, and quality assurance to obtain highly purified biopharmaceuticals or vaccines.
Raju Khan, Arpana Parihar, Ajeet Kumar Kaushik + 1 more
March 4, 2022
9 7 8 - 0 - 1 2 - 8 2 4 4 9 4 - 4
9 7 8 - 0 - 3 2 3 - 8 5 9 8 9 - 9
Advanced Biosensors for Virus Detection: Smart Diagnostics to Combat Against the SARS-CoV2 Pandemic covers the development of biosensor-based approaches for the diagnosis and prognosis of viral infections, specifically coronaviruses. The book discusses wide-ranging topics of available biosensor-based technologies and their application for early viral detection. Sections cover the emergence of SARS-CoV, MERS-CoV and SARS-CoV2, the global health response, the impact on affected populations, state-of-the art biomarkers, and risk factors. Specific focus is given to COVID-19, with coverage of genomic profiling, strain variation and the pathogenesis of SARS-CoV2. In addition, current therapeutics, nano-abled advancements and challenges in the detection of SARS-CoV2 and COVID-19 management are discussed, along with the role of nanomaterials in the development of biosensors and how biosensors can be scaled up for clinical applications and commercialization.
Advanced Mathematical Modelling of Biofilms and its Applications covers the concepts and fundamentals of biofilms, including sections on numerical discrete and numerical continuum models and different biofilms methods, e.g., the lattice Boltzmann method (LBM) and cellular automata (CA) and integrated LBM and individual-based model (iBM). Other sections focus on design, problem-solving and state-of-the-art modelling methods. Addressing the needs to upgrade and update information and knowledge for students, researchers and engineers on biofilms in health care, medicine, food, aquaculture and industry, this book also covers areas of uncertainty and future needs for advancing the use of biofilm models. Over the past 25-30 years, there have been rapid advances in various areas of computer technologies, applications and methods (e.g. complex programming and algorithms, lattice Boltzmann method, high resolution visualization and high-performance computation). These new and emerging technologies are providing unprecedented opportunities to develop modeling frameworks of biofilms and their applications.
Satish Chandra Pandey, Veni Pande, Diksha Sati + 1 more
January 27, 2023
9 7 8 - 0 - 3 2 3 - 9 1 6 4 3 - 1
9 7 8 - 0 - 3 2 3 - 9 1 6 4 4 - 8
Advanced Microbial Techniques in Agriculture, Environment, and Health Management provides current perspectives on the fields of agriculture, the environment and health. This important reference presents recent advancements in applied microbial technology, compiling it in a comprehensive manner and transferring applied microbial technology from laboratory conditions to field level. In 20 chapters, the book focuses on microbial interventions for all-inclusive, cost-effective environmental management tactics while also linking the cumulative microbial services involved in the up-gradation of agriculture, environment and health. In addition, the book offers detailed information on emerging environmental issues and proposes ways of controlling their consequences using different approaches to treatment.
Saurabh Gangola, Saurabh Kumar, Samiksha Joshi + 1 more
May 18, 2023
9 7 8 - 0 - 3 2 3 - 9 5 0 9 0 - 9
9 7 8 - 0 - 3 2 3 - 9 5 0 9 1 - 6
Advanced Microbial Technology for Sustainable Agriculture and Environment focuses on plant-microbe interactions in respect to bioremediation and plant growth promotion, providing insights on diverse approaches such as genomics, metagenomics, proteomics, bioinformatics and other high-throughput analyses of environmentally relevant microorganisms. The impact of frequent applications of potentially toxic chemicals (pesticides and fertilizers) and increased industrialization processes on microbial diversity emphasizes the potential threat to microbial biodiversity in ecosystems. This is an ideal resource on current trends and the future of PGPR developments with bioremediation potential.Moreover, it gives a deep understanding of the genetics of microbial biodegradation and different remediation mechanisms that help to re-establish the natural environment.
Advances in Antiparasitic Therapies and Drug Delivery systematically discusses the fundamentals, principles, and methods of molecular mixing and reaction process intensification. The book demonstrates, in detail, the implementation approach, process, and effectiveness of Higee chemical reaction engineering through novel industrial case studies that help industrial technicians to select reaction intensification technology route more scientifically. Sections cover the innovation and development process of Higee chemical reaction engineering, hydrodynamics behavior in Higee reactors, equipment design principles and methods, multiphase reaction of liquid-liquid, gas-liquid, gas-solid, gas-liquid-solid and reactive crystallization process intensification principles and effectiveness.The book is a systematic summary of several national award and key projects, such as the State Technological Innovation Award, State Science and Technology Advancement Award, National Natural Science Foundation of China, National key R&D Program of China, National ‘‘863’’ Program of China, National ‘‘973’’ Program of China and also some international cooperation.
The fourth volume of Advances in Antiviral Drug Design is keeping up with the recent progress made in the broad field of antiviral drug research and encompasses six specific directions that have opened new avenues for the treatment of HIV and other virus infections.First, as the introductory chapter, the different new anti-HIV agents that are now in preclinical or clinical development are reviewed by E. De Clercq. This includes new NRTIs, NNRTIs and PIs, but also HIV entry/fusion inhibitors as well as integrase inhibitors, and some of these agents, such as the NRTI emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed for clinical use.Second, high expectations are vested in the potential therapeutic usefulness of inhibitors of HIV integration, a point of no return in the life cycle of HIV, and this approach is highlighted by D.J. Hazuda and S.D. Young.Third, as all currently available PIs can be described as "peptidomimetic", and, therefore, expected to demonstrate overlapping virus-drug resistance and side effect profiles, it would be interesting to see how a non-peptidic protease inhibitor such as tipranavir behaves, and this is covered by D. Mayers, K. Curry, V. Kohlbrenner and S. McCallister.Fourth, neuraminidase inhibitors such as zanamivir (that has to be inhaled) and oseltamivir (that can be administered via the oral route) have gained a definitive status as antiviral drugs useful for both therapy and prophylaxis of influenza A and B virus infections; as they target a specific influenza viral enzyme, neuraminidase (or sialidase), they may be expected to block newly emerging influenza viruses as well, and the design of neuraminidase inhibitors has received due attention of H. Jin and C.U. Kim.Fifth, while the major current efforts in antiviral drug development have shifted from herpesviruses towards HIV and hepatitis viruses [hepatitis B virus (HBV), hepatitis C virus (HCV)], it is interesting to note that by switching from the classical five-membered sugar or acyclic nucleoside strategy, J. Wang, M. Froeyen and P. Herdewijn have gone "upstream" in designing six-membered carbocyclic nucleosides as potential anti-herpesvirus agents.Sixth, following up on the nucleotide prodrug strategy introduced above under ix, to deliver the biologically active nucleotides inside the cells, C. Meier has elaborated on a particular class of such pronucleotides, namely that of the cyclosaligenyl pronucleotides, an approach that should have far reaching implications for compounds effective against HIV, HBV and other viruses.The six topics covered in this fourth volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the design and development of new therapeutic agents for virus infections. They pertain to the combat against three of the most important viral pathogens of current times: HIV, HBV, influenza virus and herpesviruses.
Regularly reviewing the "state-of-the-art" developments in the antiviral drug research field, this latest volume spans the conceptual design and chemical synthesis of new antiviral compounds. It discusses their structure-activity relationship, mechanism and targets of action, pharmacological behavior, antiviral activity spectrum, and therapeutic potential for clinical use.
Volume 3 of Advances in Antiviral Drug Design is keeping up with the recent progress made in the field of antiviral drug research and highlights five specific directions that have opened new avenues for the treatment of virus infections. First, the use of lamivudine (3TC) for the treatment of HIV infections, and its more recent introduction for the treatment of hepatitis B virus (HBV) infections, has heralded the transition of D- to L-nucleosides in the antiviral nucleoside drug design, and it is likely that the future will provide more nucleosides of the L-configuration, such as (-)FFC (emtricitabine) and L-FMAU, as will be described by J.-C.G. Graciet and R.F. Shinazi. Second, the acyclic purine nucleoside phosphonates, i.e. PMEA (adefovir and PMPA (tenofovir), offer great potential as both anti-HIV and anti-HBV agents, and both compounds have been the subject of advanced clinical trials in their oral produrg form (adefovir dipivoxil and tenofovir disoproxyl), as mentioned by M.N. Arimilli, J.P. Dougherty, K.C. Cundy, and N. Bischofberger.Third, with the advent of nevirapine, delavirdine, and efavirenz, the NNRTIs have definitely come of age. Emivirine (MKC-442), a derivative of the original HEPT analog that was described in 1989 has now proceeded through pivotal clinical studies, and how this class of compounds evolved is presented in the account of H. Tanaka and his colleagues. Fourth, at the end of 1999, anticipating on the next winter influenza offensive, we should have at end two compounds that specifically inhibit influenza A and B virus infections: zanamivir (by the intranasal route) and oseltamivir (by the oral route). Both compounds have proved effective in the prophylaxis and treatment of influenza A and B virus infections and act through the same mechanism; that is by blocking the viral neuraminidase (or sialidase), a key enzyme that allows the virus to spread from one cell to another (within the respiratory mucosal tract). The design of these sialidase inhibitors will be presented by M. von Itzstein and J.C. Dyason.Fifth, the discovery (in 1996) of the chemokine receptors CXCR4 and CCR5 as essential coreceptors (in addition to the CD4 receptor) for HIV entry into the cells, has boosted an enormous interest in potential antagonists of these receptors. The bicyclams represent the first low-molecular-weight compounds targeted at CXCR4, the coreceptor used by the more pathogenic, T-lymphotropic, HIV strains, to enter the cells. They will be addressed by G.J. Bridger and R.T. Skerlj.The five topics covered in this third volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the chemotherapy of virus infections. They pertain to the combat against three of the most important virus infections of current times: HIV, HBV, and influenza virus.